Michael Pro, MD
Ophthalmology · Bala Cynwyd, PANPI 1639137524
Payments from drug & device makers
Across 147 payments — averaging $239.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$19K
- Alcon$12K
- Glaukos Corporation$2K
- Sight Sciences, Inc.$1K
- AbbVie$635
- Ivantis, Inc$258
- plus $633 from 11 others
What the payments were for
- Consulting fees$12,32535%
- Speaking & faculty fees$15,00043%
- Travel & lodging$1,3024%
- Food & beverage$6,50218%
- Education$800%
- Gifts$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 23 | $18,732 |
| Alcon | 28 | $12,094 |
| Glaukos Corporation | 14 | $1,503 |
| Sight Sciences, Inc. | 23 | $1,417 |
| AbbVie(2 entities) | 24 | $635 |
| Ivantis, Inc | 2 | $258 |
| Novartis | 14 | $206 |
| Aerie Pharmaceuticals, Inc. | 6 | $109 |
| Ellexiscience | 1 | $106 |
| Bausch & Lomb Americas Inc. | 4 | $68 |
| Dompe US, Inc. | 1 | $34 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $30 |
| Biotissue Holdings Inc. | 1 | $23 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$18,153
- Kahook Dual Blade$18,153
- Clearpath$14,994
- Streamline$14,994
- Via360$13,794
- Hydrus Microstent$10,546
- OMNI(R) SURGICAL SYSTEM (US)$793
- iDoseTR$354
- OMNI$231
- Streamline Surgical System$159
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$148
- iStent infinite Trabecular Micro-Bypass System Model iS3$148
- iDose$137
- SION SURGICAL INSTRUMENT$134
- LUMIGAN$125
- Hydrus$125
- iStent inject Trabecular Micro-Bypass Stent System$100
How this compares
$35,272 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 416 | $199,680 |
| RestasisCyclosporine | 29 | $48,276 |
| CombiganBrimonidine Tartrate/Timolol | 121 | $47,910 |
| Brimonidine Tartrate | 854 | $38,525 |
| RhopressaNetarsudil Mesylate | 79 | $38,188 |
| RocklatanNetarsudil Mesylat/Latanoprost | 70 | $36,682 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 188 | $36,405 |
| VyzultaLatanoprostene Bunod | 62 | $33,823 |
| Alphagan PBrimonidine Tartrate | 104 | $32,381 |
| Prednisolone Acetate | 562 | $29,454 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 90 | $21,047 |
| Brinzolamide | 83 | $20,068 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,094 | $18,497 |
| Latanoprost | 1,477 | $14,387 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 57 | $12,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $635 | $328,246670 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $109 | $74,870149 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $68 | $33,82362 claims |
| AlconSimbrinza | $12,094 | $21,04790 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $30 | $5,11017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Bala Cynwyd
- Brandon AyresBala Cynwyd$1.3M
- Tina XiaBala Cynwyd$134K
- Richard TippermanBala Cynwyd$111K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.